PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma by Guanzhen Yu et al.
Yu et al. Molecular Cancer  (2015) 14:193 
DOI 10.1186/s12943-015-0462-6RESEARCH Open AccessPKM2 regulates neural invasion of and
predicts poor prognosis for human hilar
cholangiocarcinoma
Guanzhen Yu1,6*†, Wenlong Yu2†, Guangzhi Jin3†, Dongyun Xu1†, Ying Chen4, Tian Xia5,6, Allan Yu6,
Wenzheng Fang1, Xiaoli Zhang7, Zhaosheng Li5* and Keping Xie6*Abstract
Background: The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase,
and pyruvate kinase (PK) has been implicated in a variety of cancers, while their roles in treatment of and prognosis
for hilar cholangiocarcinoma (HC) remain unclear. In this study, we determined the expression of PKM2 in and its
impact on biology and clinical outcome of human HC.
Methods: The regulation and function of PKM2 in HC pathogenesis was evaluated using human tissues, molecular
and cell biology, and animal models, and its prognostic significance was determined according to its impact on
patient survival.
Results: We found that expression of hexokinase 1 and the M2 splice isoform of PK (PKM2) was upregulated in HC
tissues and that this expression correlated with tumor recurrence and outcome. PKM2 expression was increased in
HC cases with chronic cholangitis as demonstrated by isobaric tags for relative and absolute quantification. High
PKM2 expression was highly correlated with high syndecan 2 (SDC2) expression and neural invasion. PKM2
downregulation led to a decrease in SDC2 expression. Treatment with metformin markedly suppressed PKM2
and SDC2 expression at both the transcriptional and posttranscriptional levels and inhibited HC cell
proliferation and tumor growth.
Conclusions: PKM2 regulates neural invasion of HC cells at least in part via regulation of SDC2. Inhibition of
PKM2 and SDC2 expression contributes to the therapeutic effect of metformin on HC. Therefore, PKM2 is an
independent prognostic factor and potential therapeutic target for human HC.
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Hilar cholangiocarcinoma (HC) is a complex, aggressive
disease with an extremely poor prognosis. R0 resection
offers the only chance for long-term survival of HC.
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the progression of HC [2]. Additionally, the presence of
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and overall survival (OS) [2–4]. However, physicians
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obic glycolysis, known as the Warburg effect, to maintain
the growth and survival of cancer cells [5]. Investigators
have well established that accelerated aerobic glycolysis is
associated with activation of oncogenes or inhibition of
tumor suppressors in certain cells [6]. Three rate-limiting
enzymes active in glycolysis—hexokinase (HK), pyruvate
kinase (PK), and phosphofructokinase (PFK)—are widely
activated in cancer cells [7]. HK2, which is highly expressed
in cancer cells, is thought to be required for tumor initi-
ation and maintenance, and HK2 deletion is therapeutic in
mouse models of cancer [8]. Few studies have demon-
strated that HK1 is associated with therapeutic effective-
ness against cancer [9, 10]. Unlike other PK isoforms,
PKM2 contributes to tumorigenesis [11]. Elevated PKM2
expression correlates with poor outcomes of cancer [12].
In addition, expression of 6-phosphofructo-2-kinase/fruc-
tose-2,6-biphosphatase 4 (PFKFB4), an isoform of PFK2, is
elevated in tumors and an important regulator of cancer
cell survival [13]. Additionally, key regulators of aerobic
glycolysis are implicated to play roles in predicting out-
come and monitoring drug resistance of HC. Therefore,
targeting cancer metabolism seems to be a promising
therapeutic approach [14].
Continuous progress in research of the cancer meta-
bolic program has increased our understanding of can-
cer biology and helped identify novel therapeutic targets
and/or predictive biomarkers. However, little is known
about the status of the key enzymes HK, PK, and PFK in
HC pathogenesis and treatment. However, researchers
rarely have explored the therapeutic and prognostic
value of glycolytic molecules, including HK, PFKB, and
PKM2, regarding HC. Therefore, in the present study,
we sought to determine the prognostic value of these
three glycolytic enzymes in HC cases and investigated
the possible mechanisms underlying PKM2’s promotion
of HC growth and NI.Results
Increased HK1 and PKM2 expression in HC samples
Immunohistochemical analysis found that HK1 and
PKM2, but not PFKB expression, was higher in tumor
than in normal tissue samples (Fig. 1). Expression of
HK1 and PKM2 protein was markedly higher in tumor
than in noncancerous tissue samples (Fig. 1a). The rates
of high HK1 and PKM2 expression were 63 % (55/88)
and 53 % (47/88), respectively. High PFKB was
expressed in 56 % (49/88) cases, but its expression pat-
tern did not correlate with normal versus tumor tissue
alone. These results were further confirmed by Western
blotting which revealed a higher expression of HK1 and
PKM2, but not PFKB expression, in tumor than in nor-
mal tissue samples (Additional file 1: Fig. S1).Correlation of High HK1 and PKM2 expression with
clinicopathological characteristics in HC patients
The association of high HK1, PKM2, and PFKB expres-
sion with clinicopathological factors for HC is shown in
Additional file 2: Table S1. PFKB expression was associated
with T1 and T2 tumors (P = 0.014). High HK1 expression
was significantly associated with lymph node metastasis
(P < 0.001) and stage III and IV disease (P = 0.006). High
PKM2 expression was associated with NI (P = 0.001),
lymph node metastasis (P = 0.001), and poor or lack
of tumor differentiation (P = 0.001) (Additional file 2:
Table S1). These data revealed that HK1 and PKM2
expression is significantly correlated with lymph node
metastasis of HC but that PFKB expression is not.
Additionally, PKM2 expression correlated significantly
with NI of HC.
Correlation of high HK1 and PKM2 expression with
recurrence and survival in HC patients
The median disease-free survival (DFS) duration in the HC
patients was 14 months, whereas the median OS duration
was 16 months. Patients with high HK1-expressing tumors
had significantly shorter median DFS durations than did
patients without them (12 months versus 39 months;
P = 0.012) (Fig. 1b). Similarly, patients with high PKM2-
expressing tumors had significantly shorter DFS durations
than did patients without them (11 months versus 32
months; P < 0.001) (Fig. 1c). High PFKB expression was not
associated with DFS duration (Additional file 1: Fig. S2A).
Other factors associated with HC recurrence in our univar-
iate analysis were tumor invasion (P < 0.001), surgery type
(P < 0.001), lymph node metastasis (P = 0.002), tissue differ-
entiation (P = 0.017), and TNM category (P = 0.019).
As for OS, HC patients with high HK1-expressing tu-
mors had a median duration of 15 months, whereas pa-
tients without them had a median duration of 46
months (P = 0.013) (Fig. 1d). Similarly, patients with high
PKM2-expressing tumors had a shorter median survival
duration than did those without them (14 months versus
40 months; P < 0.001) (Fig. 1e). High PFKB expression
did not correlate with OS duration (Additional file 1:
Fig. S2B). The other valuable factors in univariate ana-
lysis of OS were tumor invasion (P < 0.001), lymph node
metastasis (P = 0.002), surgery type (P < 0.001), tissue dif-
ferentiation (P = 0.017), and TNM category (P = 0.016).
Expression of PKM2, but not HK1, as an independent
prognostic factor in HC patients
Multivariate analysis demonstrated that T category,
lymph node metastasis, surgery type, and high PKM2 ex-
pression were independent predictors of HC recurrence
(Additional file 2: Table S2) and independent prognostic
factors (Additional file 2: Table S3). Furthermore, subgroup














































































Fig. 1 HK1, PKM2, and PFKB expression and its association with survival durations in patients with HC. a, HK1, PKM2, and PFKB expression in normal bile
duct tissue (left panels), tumors (middle panels), and quantitative representations staining (right panels). Original magnification, ×400. b, patients with
high HK1 expression had a shorter median time to recurrence than did those with low HK1 expression (12 months versus 39 months). Cum, cumulative.
c, patients with high PKM2-expressing tumors had a significantly shorter median time to recurrence than did patients with low PKM2-expressing tumors
(11 months versus 32 months). d, the median OS duration was significantly worse in patients with high expression of HK1 (15 months) than in those
with low expression of HK1 (46 months). e, the median OS duration was significantly worse in patients with high expression of PKM2 (14 months) than
in those with low expression of PKM2 (40 months)
Yu et al. Molecular Cancer  (2015) 14:193 Page 3 of 13revealed that patients with high PKM2-expressing tumors
had shorter DFS durations than did those without such tu-
mors in each category (Additional file 1: Fig. S3A and S3B).Similarly, HC patients with high PKM2-expressing tumors
had a shorter median survival duration than did patients
without them in every TNM category (Additional file 1:
Yu et al. Molecular Cancer  (2015) 14:193 Page 4 of 13Fig. S3C and S3D). Therefore, PKM2 appears to be a more
sensitive biomarker than HK1 in monitoring HC recur-
rence and predicting HC outcome.
Upregulation of PKM2 expression in patients with
inflammation-related HC
Given evidence that biliary tract stone disease is an
established HC risk factor, we analyzed protein expres-
sion changes in tumor samples obtained from patients
with HC and biliary tract stone disease and compared
them with those in inflammatory biliary tract tissue sam-
ples using an isobaric tags for relative and absolute quanti-
fication assay. We identified changes in the expression of
60 proteins using MS analysis (data not shown). PKM2 ex-




Fig. 2 PKM2 protein expression profiles in tissue samples obtained from pa
biliary intraepithelial neoplastic lesion (IEN), primary tumor, invasive tumor,
staining in the samples increased with the progression of HC: 0.36 ± 0.48 in
stage III, and 2.00 ± 1.25 in stage IV samples. c, the PKM2-positivity rates in cho
% (0/3), 0 % (0/6), 52 % (16/31), 60 % (27/45), and 67 % (4/6), respectivelynoncancerous in the inflammatory tissue samples. These
data further supported a potential role for PKM2 in the
initiation of HC (Additional file 1: Fig. S4).
Direct correlation of PKM2 protein expression with HC
progression
We then systemically analyzed the PKM2 expression lo-
cations and profiles in HC samples. PKM2 expression
was predominantly located in the cytoplasm of HC cells
(Fig. 2a). However, we observed nuclear staining for
PKM2 in the invasion margins of primary tumors, meta-
static lesions, and poorly differentiated and undifferenti-
ated HC cells (Fig. 2a and Additional file 1: Fig. S5). The
mean ± SD intensity of PKM2 staining increased with

































tients with HC at different stages. a, expression of PKM2 in cholangitis,
and metastatic tumor samples. b, the mean ± SD intensity of PKM2
cholangitis, 0 in IEN, 0 in stage I, 1.11 ± 1.11 in stage II, 1.61 ± 1.26 in
langitis, hyperplasia, and stage I, II, III, and IV samples were 14 % (4/28), 0
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ease, 1.6 ± 1.26 for stage III disease, and 2.00 ± 1.25 for
stage IV disease (Fig. 2b). Similarly, the PKM2-positivity
rates for cholangitis, hyperplasia, and stage I, II, III, and
IV disease were 14 % (4/28), 0 % (0/2), 0 % (0/6), 52 %
(16/31), 60 % (27/45), and 67 % (4/6), respectively (Fig. 2c).
These data provided strong clinical evidence of a critical
role for PKM2 expression in HC development.
Association of high PKM2 expression with NI of HC
Perineural invasion (PNI) is a common event in HC me-

























Fig. 3 Association between PKM2 expression and PNI of HC. a, HC patients wi
PNI (15 months versus 27 months). Cum, cumulative. b, the PKM2 staining sco
c, HC cells surrounding nerve fibers (S100) exhibited strong staining for PKM2.
spreading via local infiltration and metastasis all exhibited intense cytoplasmicDFS duration in HC patients without PNI was clearly
longer than that in patients with PNI (26 months versus
15 months; P = 0.017) (Fig. 3a). Tumors with PNI had
higher PKM2-positivity rates and PKM2 staining inten-
sity than did those without PNI (Additional file 2: Table
S1 and Fig. 3b). Except for those surrounding nerve fi-
bers (Fig. 3c), all HC cells that entered the perineurium
and spread via local infiltration and metastasis exhib-
ited intense cytoplasmic staining for PKM2 (Fig. 3d).
This clinical evidence demonstrated a strong associ-
ation between cytoplasmic PKM2 expression and PNI











th PNI had a shorter median time to recurrence than did those without
re was higher for tumors with PNI than for tumors without PNI (P = 0.0369).
Original magnification, ×400. D, HC cells entering the perineurium and
staining for PKM2. Original magnification, ×200
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To provide direct evidence of the critical role of PKM2
expression in NI of HC, we determined the effect of
knocking down PKM2 expression with shRNA on the
PNI of HC cells in vivo. Silencing of PKM2 expression
remarkably inhibited both tumor growth and metastasis
in mice as revealed by anatomical and ultrasonic assays
(Fig. 4a-4c and Additional file 1: Fig. S6A and S6B).
However, mice harboring high PKM2-expressing tumors
did not have longer survival durations than those of
mice harboring low PKM2-expressing tumors (Fig. 4d).
A histopathological study demonstrated higher rates of
PNI in control mice than in the PKM2-knockdown
group (Fig. 4e and 4f). Immunohistochemical staining

















Fig. 4 Knockdown of PKM2 expression led to inhibition of NI of HC cells in
assess the inhibitory effect of PKM2 knockdown (a) compared with in a negat
(right) methods. c and d, tumors were weighed (c) and survival durations
e, histological (E1) and immunohistochemical (E2) assays demonstrated N
NI of tumors with low PKM2 expression was rare (PKM2-knockdown group; E4).
HC in the PKM2-knockdown and control groups. g, graphical representation ofand PNI (Fig. 4e and 4g). These experimental data were
consistent with our clinical observation, supporting a
critical role for PKM2 expression in NI and metastasis
of HC.
PKM2-knockdown downregulated SDC2 expression
To determine the underlying mechanisms of PKM2’s
regulation of PNI of HC, we measured the mRNA levels
for molecules and metastasis-related genes possibly re-
lated to PNI. Expression of nerve growth factor (NGF),
SDC2, matrix metalloproteinase (MMP) 7 and MMP9,
sodium-coupled neutral amino acid transporter 1, and
protocadherin 9 (PCDH9) was lower and that of metas-
tasis suppressor 1 was higher in mice with knockdown


































































mice in vivo. a and b, in situ tumor xenograft models were used to
ive control (NC) (b) as determined using anatomical (left) and ultrasonic
were calculated (d) at the end of the experiment. Cum, cumulative.
I of tumors with high PKM2 expression (control group; E3), whereas
Original magnification, ×200. f, graphical representation of the rate of NI of
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0
Fig. 5 Correlation between PKM2 expression and SDC2 expression in HC cases. QBC939 cells were transiently transfected with control shRNA or
PKM2 shRNA. a and b, the expression of several genes associated with NI and metastasis was measured using reverse transcription-polymerase
chain reaction (a), and the level of PKM2 and SDC2 expression was determined using Western blotting (b). GAPDH, glyceraldehyde-3-phosphate
dehydrogenase. c, graphical representation demonstrating a significant correlation between PKM2 expression and SDC2 expression in human HC
tissues. d, co-localization of PKM2 and SDC2 in the consecutive sections of HC tissue. e, co-localization of PKM2 and SDC2 in the consecutive sections
of HC tissue with NI. Original magnification, ×40 (left) and × 400 (right)
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SDC2 expression in QBC939 cells (Fig. 5b). As shown in
Additional file 2: Table S4, we observed significant asso-
ciations of SDC2 expression with NI, infiltration, and ad-
vanced stage of HC. Patients with SDC2-expressing tumors
had a worse median OS duration than did those without
such tumors (17 months versus 26 months; P = 0.025)
(Additional file 1: Fig. S7).
Next, we analyzed PKM2 and SDC2 protein expres-
sion in HC cells and observed a significant correlation
between the two biomarkers (r = 0.428; P < 0.001) (Fig. 5c
and Additional file 2: Table S5). Furthermore, we observed
co-expression of PKM2 and SDC2 in 42 % (37/88) tumors
and no expression of either of them in 30 % (26/88) tu-
mors. In the majority of the cases, PKM2 expression co-
localized with SDC2 expression in the same cells from thesame samples (Fig. 5d and 5e). These data provided a
cross-talk between PKM2 and SDC2, which might play a
role in promotion of NI of HC.Inhibition of HC cell growth via blockade of PKM2 and
SDC2 expression by treatment with metformin
Metformin’s anticancer effects are exerted partially by
blocking HK activation. Our data revealed that treatment
with metformin inhibits HC cell viability in a dose-
dependent manner in vitro (Fig. 6a and Additional file 1:
Fig. S8A) and inhibits tumor growth (Fig. 6b and 6c). Also,
treatment with metformin decreased both PKM2 and
SDC2 expression in vitro and in vivo (Fig. 6d and 6e).
These data suggested that treatment with metformin inhib-
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Fig. 6 Treatment with metformin inhibited HC cell proliferation and tumor growth via suppression of PKM2 and SDC2 expression. a, QBC939 cells
was treated with metformin at different concentrations (0, 10, 20, and 50 mM), and their viability was measured at 24 and 72 h after treatment
using an MTT assay. b, Western blotting was used to determine the level of PKM2 and SDC2 expression after treatment with metformin. PBS,
phosphate-buffered saline. c and d, in situ tumor xenograft models were used to assess the inhibitory effect on tumor growth of treatment with
metformin (250 mg/kg) compared with that in a negative control. Tumor weights (c) and representative tumors from each group (d) were measured
at the end of the experiment. e, PKM2, SDC2, and PCNA were detected in the xenograft tumors using immunohistochemistry
Yu et al. Molecular Cancer  (2015) 14:193 Page 8 of 13PKM2/SDC2 axis, supporting our hypothesis that metfor-
min has an important role in HC treatment.
Discussion
In this study, we systematically analyzed the expression
profiles of key glycolytic enzymes in patients and mice
with HC and found that expression of HK1 and PKM2
was markedly increased and correlated with tumor pro-
gression. High PKM2 expression was an independent
predictor of recurrence and survival after resection of
HC. Additionally, high PKM2 expression correlated dir-
ectly with NI and NI-related biomarkers, especiallySDC2, suggesting a novel molecular basis for the role of
PKM2 in HC development and progression.
Aerobic glycolysis is essential for tumorigenesis, and the
glycolytic enzymes HK, PFK, and PK are now recognized as
potential therapeutic targets for cancer [14]. Researchers
have also linked biological markers of glycolysis (HK2,
PFKFB4, PKM2, etc.) with tumor recurrence and OS in cer-
tain cancer patients [12]. Previous studies demonstrated
that expression of HK2 but not HK1 was a significant
predictor of survival [16, 17]. Few studies have identified
the prognostic value of PFKFB4 regarding tumor recur-
rence and/or survival [13]. Other studies demonstrated a
Yu et al. Molecular Cancer  (2015) 14:193 Page 9 of 13significant correlation between PKM2 expression and
overall prognosis for cancer [18, 19]. However, researchers
rarely have explored the therapeutic and prognostic value
of glycolytic molecules, including HK, PFKB, and PKM2,
regarding HC. Therefore, in the present study, we investi-
gated the HK1, PFKB, and PKM2 expression statuses in
HC samples and cells and found that HK1 and PKM2 ex-
pression but not PFKB expression was higher in tumor
than in normal tissue samples. Specifically, HK1 expression
was associated with lymph node metastasis and advanced
disease stage, whereas PKM2 expression correlated with
NI, tumor invasion, lymph node metastasis, and poor or
lack of tumor differentiation, suggesting that sustained aer-
obic glycolysis is a feature of biologically aggressive tumors.
Moreover, survival analysis demonstrated that expression
of HK1 and PKM2 was associated with recurrence of and
prognosis for HC. However, our multivariate analysis dem-
onstrated that expression of PKM2, but not HK1, was an
independent predictor of survival of HC. Interestingly, pa-
tients with PKM2 expression had shorter times to recur-
rence and worse outcomes at both early and late stages of
HC than did those without PKM2 expression. These find-
ings further confirmed that aerobic glycolysis is essential
for development of HC and that PKM2 is a useful bio-
marker for predicting HC recurrence and outcome.
A variety of risk factors for HC are well established, in-
cluding chronic inflammation of biliary ducts and cirrhosis
[1]. Also, a previous study identified the proteomic signa-
tures associated with lung cancer and chronic obstructive
pulmonary disease and revealed that the relevant signaling
between the two diseases was related to inflammatory sig-
naling and gluconeogenesis pathways [20]. Consistent with
these findings, we observed overexpression of inflamma-
tory signaling (ANXA4, ANXA6, etc.) (data not shown)
and glycolysis (PKM2) pathways in HC and chronic in-
flammation of biliary ducts, suggesting that PKM2 expres-
sion contributes to tumorigenesis induced by chronic
inflammatory diseases for certain cancers. Further analysis
revealed that PKM2 expression was gradually upregulated
as HC progressed. The predominant expression pattern
was increased cytoplasmic PKM2 expression in cancer
cells. However, we found nuclear staining for PKM2 at the
front edges of invasion margins of primary tumor and
metastatic cells. Therefore, nuclear PKM2 expression may
be important to HC invasion and metastasis.
NI is highly associated with postoperative recurrence
of and poor prognosis for HC [15]. Researchers have
demonstrated that the molecules NGF, neural cell adhe-
sion molecule, MMP, Ach, and transforming growth fac-
tor may predict NI of HC. In the present study, we
found that the PKM2 expression rate in HC cases with
NI was markedly higher than that in cases without NI,
indicating that PKM2 may participate in the NI process.
Moreover, PKM2 expression increased along with neuralinvasiveness of HC, and we observed cytoplasmic PKM2
expression at each step of NI, indicating a relationship
between PKM2 expression and HC cells’ ability to ad-
here to, invade into, and survive in nervous tissue and
thus metastasize via the nervous system. The critical role
of PKM2 in tumorigenesis in promoting the Warburg ef-
fect makes PKM2 an attractive target for cancer therapy.
However, PKM2 knockdown has not affected the growth
of different types of tumors owing to the fact that slowing
glycolysis generates macromolecule precursors, which sup-
port cell proliferation [14]. In our study, we observed mod-
est impairment of survival and proliferation of HC cells
after knocking down PKM2 expression. However, the rate
of NI of tumors with PKM2 expression was markedly
higher than that of NI of tumors without PKM2 expres-
sion. Meanwhile, PKM2 was weakly expressed in normal
nervous tissue, suggesting an ectopic relationship between
PKM2 expression and this tissue. These data suggest that
PKM2 expression is positively correlated with NI of HC
and is an indicator of NI of and prognosis for HC.
Mechanistically, in HC cells, knockdown of expression
of PKM2 decreased the expression of NGF, MMP7,
MMP9, and SDC2, molecules potentially related to NI.
NGF facilitates cancer cell proliferation by binding to TrkA
receptors in the perineurium [21]. MMP7 and MMP9 are
expressed in cancer cells that invade nervous tissue [15].
SDC2 is a novel PNI-associated gene in pancreatic adeno-
carcinoma cases, with SDC2 silencing markedly reducing
the motility and invasiveness of the cancer cells [22].
Therefore, PKM2’s mechanisms in regulating NI of HC
may be associated with NGF, MMPs, and SDC2. Addition-
ally, silencing of PKM2 leads to downregulation of expres-
sion of sodium-coupled neutral amino acid transporter 1
(a potential oncogene) [23] and upregulation of that of me-
tastasis suppressor 1 [24], supporting a crucial role for
PKM2 in tumor development and progression. However,
expression of another candidate tumor suppressor, PCDH9
[25], was remarkably decreased in HC cells when PKM2
activity was blocked, suggesting an alternative mechanism
in PKM2-knockdown-resistant cells.
Expression of the cell surface adhesion receptor SDC2
is increased in a variety of cancers [26, 27] and corre-
lated with progression and poor prognosis [28]. Our data
demonstrated that SDC2 expression was highly associated
with progression and outcome of HC. SDC2 mediates cell
adhesion and migration via several signaling pathways,
such as syntenin-1, integrin α2, and RACK1 [29–31], and
synthesis of SDC2 is enhanced by transforming growth
factor-β and melanocortin 1 receptor [32, 33]. In the
present study, we found that knockdown of PKM2 expres-
sion decreased SDC2 expression in HC cells. Clinical evi-
dence confirmed a significant correlation between PKM2
and SDC2 expression. Furthermore, PKM2 expression co-
localized with SDC2 expression in the majority of HC cells.
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SDC2, whereas 26 cases were negative for both of them, ac-
counting for 72 % of all cases. This finding suggested that
SDC2 is a novel target of PKM2 and plays an important
role in regulation of HC cell migration.
Metabolic targeting has proven to be effective in pre-
venting the development of cancer. Compounds target-
ing key metabolic steps in glycolysis have inhibited the
proliferation, invasion, and metastasis of cancer cells
[14]. Authors recently reported that treatment with met-
formin, an antidiabetic drug, acts on cell metabolism,
inhibiting all energy-consuming processes and cell pro-
liferation [34, 35]. Evidently, metformin directly inhibits
the enzymatic function of HK1 and HK2 in breast cancer
cells and markedly reduces tumor glucose consumption
and growth [36]. Our present findings are consistent with
those of previous studies in demonstrating the inhibitory
effect of treatment with metformin on HC cell prolifera-
tion and tumor growth. Furthermore, we demonstrated
that metformin decreased PKM2 and SDC2 expression in
a dose-dependent manner. These results strongly suggest
that inhibition of PKM2 and SDC2 expression contributes
to the therapeutic potential of metformin in HC patients.
Conclusions
PKM2 and HK1 were frequently overexpressed in HC
patients, and PKM2 was an independent predictor of re-
currence and OS of HC. PKM2 expression was highly
correlated with NI of HC and regulated HC cell migra-
tion via SDC2. Additionally, treatment with metformin
impaired the survival of HC cells by inhibiting expres-
sion of PKM2 and SDC2. These findings strongly sug-
gest that PKM2/SDC2 signaling plays an important role
in HC pathogenesis and is a promising biomarker for
monitoring progression and predicting OS of HC.
Methods
Patient samples and cell culture
Eighty-eight patients with previously untreated HC who
underwent curative surgery at Eastern Hepatobiliary Hos-
pital or Changhai Hospital in Shanghai, People’s Republic
of China, from 2004 to 2008 were enrolled in this study.
The patients’ characteristics are listed in Additional file 2:
Table S1. The mean age of the patients was 55 years
(range, 31–79 years). Their median follow-up duration
was 16 months (range, 1–59 months), with two patients
dying during follow-up. Three tissue microarray blocks of
tumor and matched normal bile duct tissue samples ob-
tained from these patients were created using a manual ar-
rayer (Beecher Instruments). Each block had two or three
1.5-mm cores of tumor tissue and one 1.5-mm core of
normal bile duct tissue. The institutional review boards of
both Eastern Hepatobiliary Hospital and Changhai Hos-
pital approved the use of the patients’ samples and clinicalinformation, and each patient or his or her guardian gave
informed consent to participate in the study.
The HC cell line QBC939 was purchased from the Cell
Center of the Chinese Academy of Sciences. The cells
were maintained in Dulbecco’s modified Eagle’s medium
with 10 % fetal bovine serum (Invitrogen) and cultured
at 37 °C in 5 % CO2.Immunohistochemistry and evaluation of HC specimens
Four-micron paraffin-embedded sections of the tissue
microarray blocks were prepared and processed for im-
munohistochemical analysis. HK1, PKM2, PFKB, S100,
syndecan 2 (SDC2), and proliferating cell nuclear anti-
gen (PCNA) protein expression in these sections was
detected using appropriate antibodies against HK1 (di-
lution, 1:100; YT2265; ImmunoWay), PKM2 (dilution,
1:100; EPR10138[B]; Epitomics), PFKB (dilution, 1:50;
YT3685; ImmunoWay), S100 (dilution, 1:100; 4C4.9;
Maixin-Bio), SDC2 (dilution, 1:100; 305507; R & D Sys-
tems), and PCNA (dilution, 1:100; PC10; Maixin-Bio).
A streptavidin-biotin kit (#KIT-9720; Maixin-Bio) was
used to visualize antibody binding to the sections. Pro-
tein expression in the 88 cases was evaluated by two in-
dividuals (G. Yu and Y. Chen). Any discrepancy from
the two individuals was resolved by a third individual.
A semiquantitative scoring system was used. Specifically,
the mean percentage of tumor cells positive for indicated
marker(s) was calculated in five areas of a given sample at
a magnification of × 400 and scored from 0 to 1 (0-100 %).
The intensity of immunostaining was scored as 0 for
negative, 1 for weak, 2 for moderate, and 3 for strong.
Theoretically, a weighted score was generated for each
case, ranging from 0 (0% of cells stained) to 300 (100 %
of cells stained at 3+ intensity) [37]. The cutoff points
were based on the scores: negative, 0; weak, <75; moder-
ate, 76–150; and strong, >151 (Additional file 1: Fig. S8B).
We defined the score <75 as low expression and ≥75 as
high expression [38].Protein extraction from formalin-fixed, paraffin-embedded
tissue samples; isobaric tags for relative and absolute
quantification labeling; and two-dimensional liquid
chromatography-electrospray ionization/multistage mass
spectrometry
Proteins extracted from six inflammatory bile duct tissues
and eight HC with bile duct stone disease samples were
pooled separately. Protein extraction from formalin-fixed,
paraffin-embedded samples; isobaric tags for relative and
absolute quantification labeling two-dimensional liquid
chromatography-electrospray ionization/multistage mass
spectrometry (MS/MS) and a search of relevant database
were carried out as described previously [39].
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Whole-cell lysates of HC cell lines, tumor samples, and
matched nontumor tissue samples were prepared for
Western blot analysis. Standard Western blotting [40]
was performed using rabbit antibodies against human
HK1 (1:1000), PKM2 (1:1000), PFKB (1:1000), and SDC2
(1:1000). Sample loading was monitored by probing the
same membrane filter with an anti-β-actin antibody
(sc-47778HRP; Santa Cruz Biotechnology).
Plasmids and transfection
PKM2 short hairpin RNA (shRNA) and unspecific
scrambled shRNA plasmids were gifts from Weiwei Yang
(Chinese Academy of Sciences). QBC939 cells were
digested, and 1 × 105 of the cells were seeded in six-
well plates. The cells were transfected with PKM2 or
scrambled shRNA using Lipofectamine 2000 reagent
(Invitrogen) and 5 ng of shRNA plasmid per well accord-
ing to the reagent manufacturer’s instructions. The trans-
fected cells were then subcultured and selected in the
presence of puromycin for generation of negative control
and stable PKM2-knockout cells [41].
Cell proliferation assay
Twenty-four hours after transfection, 5000 QBC939 cells
per well were seeded in 96-well plates. The parental cells
were plated onto 96-well plates and treated with metfor-
min (D6198; Sangon) at different concentrations (0, 10,
20, and 50 mM). At the indicated times, a CCK8 assay
(Dojindo) was performed to assess the final results. This
experiment was performed in triplicate.
RNA isolation and reverse transcription-polymerase chain
reaction
Total RNA was isolated from QBC939 HC cell lines
using a total RNA isolation reagent (Advanced Biotech-
nologies). cDNA was generated from 1 μg of a total
RNA sample using a transcription kit (Takara). An Ac-
cess reverse transcription-polymerase chain reaction sys-
tem (Promega) was used to measure the mRNA levels
for the indicated genes and the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase [42, 43].
Animals and animal models
Orthotropic tumor xenograft models consisting of nude male
Balb/c mice were used to assess both the inhibitory effect of
PKM2 knockdown and effect of treatment with metformin
alone. Generally, after mice were anesthetized, laparotomy
was performed, and the joint of the common bile duct and
portal vein were exposed. Tumor cells were injected into
gelatin sponges, which were placed in the joint in the bile
duct. In addition, animals were randomized into control and
treatment groups (n= 5). Metformin-based treatment (250
mg/kg) was initiated in these mice 7 days after tumor-cellinjection and was given once daily via intraperitoneal injec-
tion. The control group of mice received saline only. At 15
days after treatment, all of the mice were killed. Their
primary tumors, livers, and lymph nodes were collected and
processed for evaluation of gene expression. All animal
experiments were approved by the Animal Ethics Committee
of the Second Military Medical University [44, 45].
Statistical analysis
Statistical analysis was performed using the SPSS statis-
tical software (version 16.0; IBM Corporation) and Prism
software (version 5.0; GraphPad Software) programs. Cat-
egorical data were analyzed using χ2 tests. Differences in
protein expression between normal tissue and tumor sam-
ples were determined using the two-tailed Student t-test,
whereas the significance of the in vivo data was determined
using the two-tailed Mann–Whitney U test. Within-group
correlations of variables were assessed using Pearson’s cor-
relation coefficient. The Kaplan-Meier method was used to
estimate survival rates, and the log-rank and Wilcoxon
rank sum tests were performed to assess survival differ-
ences between groups. The Cox proportional hazards
model for multivariate survival analysis was used to assess
predictors related to survival. Two-sided P values less than
0.05 were considered statistically significant.
Additional files
Additional file 1: Figure S1. PKM2 expression in HC tissues. A, Western
blotting revealed the expression pattern of KK1, PFKB, and PKM2 in HC
(T) and matched adjacent noncancerous normal tissue (N) (A). B,
Graphical representation of the different expressions of KK1, PFKB,
and PKM2 between N and T from (A) using Image J. C, Western
blotting showed higher expressions of PKM2 in tumor (“T”) than
normal (“N”) in another three cases of HC. Figure S2. PFKB expression and HC
patient survival. Kaplan-Meier survival curves for patients with HC according to
expression of PFKB. DFS (A) and OS (B) did not differ significantly between HC
patients with low or high PFKB expression. Cum, cumulative. Figure S3.
Subgroup survival analysis of PKM2 expression in HC patients according to
TNM category. A, patients with stage I or II HC and high PKM2 expression
had a shorter median time to recurrence than did those with stage I or II
HC but without PKM2 overexpression. B, patients with stage III or IV HC and
high PKM2 expression had a significantly shorter median time to recurrence
than did patients with stage III or IV HC but with low PKM2 expression. C,
the median OS duration was significantly worse in patients with stage I or II
HC and PKM2 expression than in those with stage I or II HC but with
low PKM2 expression. D, the median OS duration was significantly
worse in patients with stage III or IV HC and PKM2 expression than
in those with stage III or IV HC but with low PKM2 expression. Cum,
cumulative. Figure S4. Representative MS/MS spectrum showing the
peptide of PKM2 protein. A, the intensity of repots ions of precursor
peptides indicating protein expression levels. N, normal bile duct tissue. B,
MS/MS spectra demonstrating identified sequences of the peptide
LAPITSDPTEATAVGAVEASFK leading to identification of PKM2. Figure S5.
Localization of PKM2 expression in HC cells. A and B, cytoplasmic staining for
PKM2 in well/moderately differentiated cancer cells. C and D, cytoplasmic
and nuclear staining (arrow) for PKM2 in poorly differentiated cancer cells.
Figure S6. Xenograft models of HC. A and B, tumor cells were treated with
either control shRNA or PKM2 shRNA and orthotopically implanted into
nude mice as described in Materials and Methods. Tumor cells with high
PKM2 expression had a higher frequency of lymph node metastasis and liver
Yu et al. Molecular Cancer  (2015) 14:193 Page 12 of 13lesions than did cells with low PKM2 expression (red arrows). C, tumors with
downregulated PKM2 expression had lower SDC2 expression than did those
with high PKM2 expression. Figure S7. Kaplan-Meier survival curves
for patients with HC according to SDC2 expression. A, patients with
high SDC2-expressing tumors had a shorter median DFS duration than did
patients with low SDC2-expressing tumors. B, the median OS duration in
patients with high SDC2 expression did not differ significantly from that in
patients with low SDC2 expression. Cum, cumulative. Figure S8. Effect of
metformin treatment on tumor cell growth. A, Metformin inhibited the
ability of cell proliferation of RBE cells in vitro as determined by using the
CCK8 assay. B, Representative photos of HC protein staining positivity and
expression pattern of IHC staining were presented. (PPTX 6948 kb)
Additional file 2: Table S1. Association between expression of PKM2,
PFKB, and HK1 and clinical variables in HC patients. Table S2. Multivariate
analysis of variables associated with TTP and OS in HC patients. Table S3.
Multivariate analysis of variables associated with OS in HC patients. Table S4.
Correlation of SDC2 expression and clinicopathological factors in HC patients.
Table S5. Correlation between PKM2 protein overexpression and SDC2
protein overexpression in HC patients. (DOCX 40 kb)
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